TABLE 1 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021- 2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 MIDDLE EAST AND AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 87 MIDDLE EAST AND AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 88 MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 MIDDLE EAST AND AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 MIDDLE EAST AND AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 91 MIDDLE EAST AND AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 92 MIDDLE EAST AND AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 93 MIDDLE EAST AND AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 94 MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 95 MIDDLE EAST AND AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 96 MIDDLE EAST AND AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 97 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 98 MIDDLE EAST AND AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 99 MIDDLE EAST AND AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 100 MIDDLE EAST AND AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 101 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 MIDDLE EAST AND AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 MIDDLE EAST AND AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 MIDDLE EAST AND AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 MIDDLE EAST AND AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 MIDDLE EAST AND AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 MIDDLE EAST AND AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 MIDDLE EAST AND AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 MIDDLE EAST AND AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 113 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 114 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 117 SOUTH AFRICA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 118 SOUTH AFRICA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 SOUTH AFRICA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 SOUTH AFRICA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 124 SOUTH AFRICA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 125 SOUTH AFRICA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 126 SOUTH AFRICA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 127 SOUTH AFRICA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 128 SOUTH AFRICA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 129 SOUTH AFRICA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 130 SOUTH AFRICA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 131 SOUTH AFRICA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 132 SOUTH AFRICA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 133 SOUTH AFRICA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 SOUTH AFRICA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 136 SOUTH AFRICA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 137 SOUTH AFRICA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 138 SOUTH AFRICA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 139 SOUTH AFRICA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 140 SOUTH AFRICA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 141 SOUTH AFRICA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 142 SOUTH AFRICA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 143 SOUTH AFRICA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 144 SOUTH AFRICA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 SOUTH AFRICA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 146 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 147 SOUTH AFRICA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 148 SOUTH AFRICA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 149 SOUTH AFRICA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 150 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 151 SOUTH AFRICA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 152 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 153 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 154 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 155 SOUTH AFRICA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 SOUTH AFRICA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 SOUTH AFRICA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 SOUTH AFRICA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 SOUTH AFRICA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 SOUTH AFRICA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 SOUTH AFRICA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 163 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 SOUTH AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 166 SAUDI ARABIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 167 SAUDI ARABIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 168 SAUDI ARABIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 169 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 170 SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 171 SAUDI ARABIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 172 SAUDI ARABIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 173 SAUDI ARABIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 174 SAUDI ARABIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 175 SAUDI ARABIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 176 SAUDI ARABIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 177 SAUDI ARABIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 SAUDI ARABIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 SAUDI ARABIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 SAUDI ARABIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 181 SAUDI ARABIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 182 SAUDI ARABIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 183 SAUDI ARABIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 184 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 185 SAUDI ARABIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 186 SAUDI ARABIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 187 SAUDI ARABIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 188 SAUDI ARABIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 SAUDI ARABIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 190 SAUDI ARABIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 191 SAUDI ARABIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 192 SAUDI ARABIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 193 SAUDI ARABIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 194 SAUDI ARABIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 196 SAUDI ARABIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 197 SAUDI ARABIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 198 SAUDI ARABIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 199 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 SAUDI ARABIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 SAUDI ARABIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 SAUDI ARABIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 SAUDI ARABIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 SAUDI ARABIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 SAUDI ARABIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 209 SAUDI ARABIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 210 SAUDI ARABIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 211 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 212 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 SAUDI ARABIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 U.A.E ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 215 U.A.E INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 216 U.A.E NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 217 U.A.E M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 218 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 219 U.A.E HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 220 U.A.E REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 221 U.A.E NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 222 U.A.E NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 223 U.A.E INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 U.A.E NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 U.A.E INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 226 U.A.E GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 227 U.A.E PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 228 U.A.E HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 229 U.A.E NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 230 U.A.E NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 231 U.A.E NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 232 U.A.E NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 233 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 234 U.A.E MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 U.A.E HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 236 U.A.E DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 237 U.A.E ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 238 U.A.E HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 U.A.E VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 U.A.E DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 241 U.A.E RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 242 U.A.E RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 U.A.E FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 244 U.A.E ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 245 U.A.E GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 246 U.A.E CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 247 U.A.E ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 248 U.A.E ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 249 U.A.E ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 250 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 251 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 U.A.E TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 U.A.E SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 U.A.E LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 U.A.E SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 U.A.E PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 UAECONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 U.A.E NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 U.A.E ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 261 U.A.E ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 U.A.E ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 EGYPT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 264 EGYPT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 265 EGYPT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 266 EGYPT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 267 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 EGYPT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 EGYPT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 EGYPT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 271 EGYPT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 272 EGYPT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 273 EGYPT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 274 EGYPT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 EGYPT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 276 EGYPT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 277 EGYPT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 278 EGYPT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 EGYPT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 280 EGYPT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 281 EGYPT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 282 EGYPT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 283 EGYPT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 284 EGYPT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 EGYPT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 286 EGYPT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 287 EGYPT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 288 EGYPT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 289 EGYPT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 EGYPT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 291 EGYPT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 292 EGYPT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 293 EGYPT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 294 EGYPT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 295 EGYPT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 296 EGYPT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 297 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 298 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 299 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 EGYPT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 EGYPT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 EGYPT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 EGYPT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 EGYPT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 305 EGYPT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 306 EGYPT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 307 EGYPT ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 308 EGYPT ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 309 EGYPT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 310 KUWAIT ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 311 KUWAIT INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 312 KUWAIT NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 313 KUWAIT M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 314 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 315 KUWAIT HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 316 KUWAIT REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 KUWAIT NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 318 KUWAIT NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 319 KUWAIT INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 320 KUWAIT NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 321 KUWAIT INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 322 KUWAIT GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 KUWAIT PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 324 KUWAIT HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 325 KUWAIT NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 326 KUWAIT NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 327 KUWAIT NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 KUWAIT NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 330 KUWAIT MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 331 KUWAIT HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 KUWAIT DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 333 KUWAIT ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 KUWAIT HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 335 KUWAIT VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 336 KUWAIT DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 337 KUWAIT RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 338 KUWAIT RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 KUWAIT FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 340 KUWAIT ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 341 KUWAIT GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 342 KUWAIT CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 343 KUWAIT ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 344 KUWAIT ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 345 KUWAIT ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 346 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 347 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 348 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 KUWAIT TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 KUWAIT SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 KUWAIT LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 KUWAIT SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 KUWAIT PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 KUWAIT CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 KUWAIT NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 KUWAIT ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 357 ISRAEL ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 358 ISRAEL INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 ISRAEL NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 360 ISRAEL M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 361 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 362 ISRAEL HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 363 ISRAEL REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 364 ISRAEL NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 365 ISRAEL NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 366 ISRAEL INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 367 ISRAEL NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 368 ISRAEL INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 ISRAEL GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 370 ISRAEL PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 ISRAEL HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 372 ISRAEL NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 373 ISRAEL NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 374 ISRAEL NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 375 ISRAEL NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 376 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 ISRAEL MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 378 ISRAEL HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 379 ISRAEL DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 380 ISRAEL ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 381 ISRAEL HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 ISRAEL VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 383 ISRAEL DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 384 ISRAEL RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 385 ISRAEL RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 386 ISRAEL FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 387 ISRAEL ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 388 ISRAEL GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 389 ISRAEL CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 390 ISRAEL ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 391 ISRAEL ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 392 ISRAEL ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 393 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 394 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 395 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 396 ISRAEL TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 397 ISRAEL SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 ISRAEL LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 ISRAEL SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 ISRAEL PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 401 ISRAEL CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 402 ISRAEL NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 403 ISRAEL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 404 ISRAEL ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 405 ISRAEL ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 406 REST OF MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)